Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to invest in now. On July 16, Morgan Stanley analyst Sean Laaman maintained a neutral stance on Halozyme Therapeutics, Inc. (NASDAQ:HALO), giving the stock a Hold rating with a $62 price target.

The analyst reasoned that one of the key concerns regarding Halozyme Therapeutics, Inc. (NASDAQ:HALO) is the uncertainty around the CMS draft pricing guidance, as it could potentially affect the pricing negotiations for the company’s combination products.

He stated that this draft guidance may be a matter of concern for Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) long-term revenues, which holds especially true if the products are not exempt from the price negotiations anticipated to take effect in 2028.

Laaman further reasoned that while Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its financial guidance for 2025 with higher partner orders and royalty revenues, it is still unclear how regulatory updates would affect these estimates.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.